MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

October 13, 2017

Guadalajara, Mexico, October 13, 2017People with drug-resistant tuberculosis (DR-TB) are still not receiving two newer tuberculosis (TB) drugs, bedaquiline and delamanid, which have shown improved cure rates for the disease, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) at the 48th Union World Conference on Lung Health in Guadalajara, Mexico, where the global TB community is meeting.

August 30, 2017

Yury*, 38, is celebrating a moment he thought would never arrive: he has been cured of extensively drug-resistant tuberculosis (XDR-TB). This moment is also a milestone for Doctors Without Borders/Médecins Sans Frontières (MSF): Yury is the first patient to complete MSF’s tuberculosis treatment program in Belarus, run in close cooperation with the Ministry of Health.

July 11, 2017

This year's G20 declaration lays out the importance of promoting research and development to combat tuberculosis' (TB) "threat to public health and economic growth." Prior to the summit, Doctors Without Borders/Médecins Sans Frontières (MSF) urged G20 leaders to take action on drug-resistant infections, including TB. View External Media.

July 06, 2017

Ahead of the G20 summit in Hamburg, where global health is on the agenda for the first time, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) called on G20 leaders to follow through on the declaration made by their health ministers in late May.

March 24, 2017

Patients with drug-resistant tuberculosis (MDR-TB) have to take a fistful of pills and injections daily for up to two years. Side effects of these toxic drugs can include permanent deafness, nausea and vomiting, blindness, and psychosis. After decades without any new TB drugs, two powerful, less toxic medicines were finally released five years ago. But most patients can't get access to them. This needs to change.

March 24, 2017

NEW YORK, MARCH 24, 2017—Today, World Tuberculosis Day, Doctors Without Borders/Médecins Sans Frontières’ (MSF) is urging pharmaceutical corporations, Sequella and Pfizer, to provide open access to all existing clinical data on a promising drug, sutezolid, to help accelerate the research and development of urgently needed new, lifesaving TB treatment regimes. This data, if not released, will take years and resources to replicate, further delaying new treatment options for people living with TB.

March 23, 2017

Companies and countries must take urgent action to increase access to these lifesaving treatments

Pages

October 13, 2017

Guadalajara, Mexico, October 13, 2017People with drug-resistant tuberculosis (DR-TB) are still not receiving two newer tuberculosis (TB) drugs, bedaquiline and delamanid, which have shown improved cure rates for the disease, said the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) at the 48th Union World Conference on Lung Health in Guadalajara, Mexico, where the global TB community is meeting.

August 30, 2017

Yury*, 38, is celebrating a moment he thought would never arrive: he has been cured of extensively drug-resistant tuberculosis (XDR-TB). This moment is also a milestone for Doctors Without Borders/Médecins Sans Frontières (MSF): Yury is the first patient to complete MSF’s tuberculosis treatment program in Belarus, run in close cooperation with the Ministry of Health.

July 11, 2017

This year's G20 declaration lays out the importance of promoting research and development to combat tuberculosis' (TB) "threat to public health and economic growth." Prior to the summit, Doctors Without Borders/Médecins Sans Frontières (MSF) urged G20 leaders to take action on drug-resistant infections, including TB. View External Media.

July 06, 2017

Ahead of the G20 summit in Hamburg, where global health is on the agenda for the first time, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) called on G20 leaders to follow through on the declaration made by their health ministers in late May.

March 24, 2017

Patients with drug-resistant tuberculosis (MDR-TB) have to take a fistful of pills and injections daily for up to two years. Side effects of these toxic drugs can include permanent deafness, nausea and vomiting, blindness, and psychosis. After decades without any new TB drugs, two powerful, less toxic medicines were finally released five years ago. But most patients can't get access to them. This needs to change.

March 24, 2017

NEW YORK, MARCH 24, 2017—Today, World Tuberculosis Day, Doctors Without Borders/Médecins Sans Frontières’ (MSF) is urging pharmaceutical corporations, Sequella and Pfizer, to provide open access to all existing clinical data on a promising drug, sutezolid, to help accelerate the research and development of urgently needed new, lifesaving TB treatment regimes. This data, if not released, will take years and resources to replicate, further delaying new treatment options for people living with TB.

March 23, 2017

Companies and countries must take urgent action to increase access to these lifesaving treatments

Pages